Cullis PR, Chonn A, Semple SC
Inex Pharmaceuticals Corporation, 100-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, B.C., V5J 5J8, Canada
Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):3-17. doi: 10.1016/s0169-409x(97)00128-2.
Liposomes and lipid-based drug delivery systems have been used extensively over the last decade to improve the pharmacological and therapeutic activity of a wide variety of drugs. More recently, this class of carrier systems has been used for the delivery of relatively large DNA and RNA-based drugs, including plasmids, antisense oligonucleotides and ribozymes. Despite recent successes in prolonging the circulation times of liposomes, virtually all lipid compositions studied to date are removed from the plasma compartment within 24h after administration by the cells and tissues of the reticuloendothelial system (RES). Plasma proteins have long been thought to play a critical role in this process but only a few efforts were made to evaluate the relevant importance of plasma protein-liposome interactions in the clearance process. Strategies to increase the bioavailability of liposomal drugs have included altering lipid compositions and charge, increasing lipid doses, and incorporating surface coatings. All of these modifications can influence membrane-protein interactions. In this article, we will focus on our experiences with liposome-blood protein interactions and how alterations in the chemical and physical properties of the carrier system influence the interactions with blood proteins and circulation times.
在过去十年中,脂质体和基于脂质的药物递送系统已被广泛用于提高多种药物的药理和治疗活性。最近,这类载体系统已被用于递送相对较大的基于DNA和RNA的药物,包括质粒、反义寡核苷酸和核酶。尽管最近在延长脂质体的循环时间方面取得了成功,但迄今为止研究的几乎所有脂质组合物在给药后24小时内都会被网状内皮系统(RES)的细胞和组织从血浆中清除。长期以来,血浆蛋白一直被认为在这一过程中起关键作用,但只有少数研究致力于评估血浆蛋白-脂质体相互作用在清除过程中的相关重要性。提高脂质体药物生物利用度的策略包括改变脂质组成和电荷、增加脂质剂量以及加入表面涂层。所有这些修饰都可以影响膜-蛋白相互作用。在本文中,我们将重点介绍我们在脂质体-血液蛋白相互作用方面的经验,以及载体系统化学和物理性质的改变如何影响与血液蛋白的相互作用和循环时间。